Danaher (NYSE:DHR) Releases Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Danaher (NYSE:DHR) posted its earnings results on Tuesday. The conglomerate reported $1.92 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.20, Briefing.com reports. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. Danaher’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period last year, the company posted $2.36 earnings per share.

Danaher Trading Down 1.8 %

NYSE:DHR opened at $245.82 on Friday. Danaher has a one year low of $182.09 and a one year high of $259.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. The firm has a market cap of $182.08 billion, a P/E ratio of 41.66, a P/E/G ratio of 4.19 and a beta of 0.83. The firm has a 50-day simple moving average of $248.94 and a 200-day simple moving average of $230.88.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 26th. Stockholders of record on Thursday, March 28th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a positive change from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 18.31%.

Wall Street Analysts Forecast Growth

DHR has been the subject of several research analyst reports. Robert W. Baird raised their target price on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and raised their target price for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Bank of America raised their target price on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research note on Wednesday. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Six investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $270.00.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Danaher news, Director Walter G. Lohr sold 3,289 shares of the business’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $251.15, for a total transaction of $826,032.35. Following the sale, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold a total of 84,132 shares of company stock valued at $21,022,795 in the last 90 days. Insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.